Assignee
RIBON THERAPEUTICS INC
US·12 granted patents·15 pending applications·43 citations·filing 2018–2024
Top patents by PatentIndex Score
27 records- 0197US11014913B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Granted May 25, 2021·6 cites·13 claims
- 0297US10550105B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·13 cites·8 claims
- 0395US11566020B1Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2021·Granted Jan 31, 2023·3 cites·26 claims
- 0494US10870641B2Pyridazinones as PARP7 inhibitorsRIBON THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·6 cites·30 claims
- 0593US11535621B2Heterobicyclic amides as inhibitors of CD38RIBON THERAPEUTICS INC·Filed 2020·Granted Dec 27, 2022·3 cites·4 claims
- 0692US11987584B2Heterobicyclic amides as inhibitors of CD38RIBON THERAPEUTICS INC·Filed 2022·Granted May 21, 2024·1 cites·22 claims
- 0792US10562891B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·5 cites·4 claims
- 0889US11293927B2Screening methods for PARP modulatorsRIBON THERAPEUTICS INC·Filed 2019·Granted Apr 5, 2022·3 cites·14 claims
- 0986US2025034120A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1085US11691969B2Pyridazinones as PARP7 inhibtorsRIBON THERAPEUTICS INC·Filed 2020·Granted Jul 4, 2023·1 cites·75 claims
- 1182US12371421B2Solid forms of a PARP7 inhibitorRIBON THERAPEUTICS INC·Filed 2020·Granted Jul 29, 2025·1 cites·20 claims
- 1282US11008308B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Granted May 18, 2021·1 cites·2 claims
- 1382US2025020654A1Screening methods for parp modulatorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1480US2023192664A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1576US2025074897A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1675US2025064803A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1773US2024325391A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1873US2022206008A1Screening methods for parp modulatorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1972US2024034728A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2068US11958837B2Quinazolinones as PARP14 inhibitorsRIBON THERAPEUTICS INC·Filed 2021·Granted Apr 16, 2024·0 cites·46 claims
- 2167US2022265654A1Dosage regimens for parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2265US2024051946A1Targeted protein degradation of parp14 for use in therapyRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2363US2024101540A1Targeted protein degradation of parp14 for use in therapyRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2461US2024190844A1Pyridazinones as parp7 inhibitorsRIBON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2561US2023303542A1Solid forms of a parp14 inhibitorRIBON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2659US2022265655A1Methods of treating inflammatory diseasesRIBON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2750US2022388985A1Targeted protein degradation of parp14 for use in therapyRIBON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when RIBON THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →